MX2016010909A - Suministro de molecula de carga util usando nanotubos de carbono discretos funcionalizados. - Google Patents

Suministro de molecula de carga util usando nanotubos de carbono discretos funcionalizados.

Info

Publication number
MX2016010909A
MX2016010909A MX2016010909A MX2016010909A MX2016010909A MX 2016010909 A MX2016010909 A MX 2016010909A MX 2016010909 A MX2016010909 A MX 2016010909A MX 2016010909 A MX2016010909 A MX 2016010909A MX 2016010909 A MX2016010909 A MX 2016010909A
Authority
MX
Mexico
Prior art keywords
carbon nanotubes
number average
discrete carbon
payload molecule
molecule delivery
Prior art date
Application number
MX2016010909A
Other languages
English (en)
Inventor
W Swogger Kurt
P Bosnyak Clive
HENDERSON Nancy
Everill Paul
Original Assignee
Molecular Rebar Design Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Rebar Design Llc filed Critical Molecular Rebar Design Llc
Publication of MX2016010909A publication Critical patent/MX2016010909A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

En diversas modalidades se divulga un sistema de suministro de molécula de carga útil o molécula de fármaco. El sistema comprende una pluralidad de nanotubos de carbono discretos funcionalizados que tienen propiedades específicas. La composición puede comprender una pluralidad de nanotubos de carbono discretos que tienen al menos una porción de los nanotubos de carbono con un promedio en número (relación de longitud de contorno promedio en número a longitud de extremo a extremo) mayor que 1.1 y de hasta aproximadamente 3. Estos nanotubos de carbono discretos que tienen la relación especificada promedio en número (relación de longitud de contorno de tubo (TCL, por sus siglas en inglés) a longitud de extremo a extremo de tubo promedio en número (TEE, por sus siglas en inglés)) no solo son discretos (separados) entre sí, sino también son controlados en su alineación de tal manera que se mejoren las propiedades de procesabilidad y resistencia mecánica. La utilidad de la composición de varilla molecular incluye, pero no se limita a, el suministro de molécula de carga útil mejorada, como suministro de fármaco, en el cuerpo de un animal, como un humano.
MX2016010909A 2014-02-21 2015-02-21 Suministro de molecula de carga util usando nanotubos de carbono discretos funcionalizados. MX2016010909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943297P 2014-02-21 2014-02-21
PCT/US2015/016992 WO2015127332A1 (en) 2014-02-21 2015-02-21 Payload molecule delivery using functionalized discrete carbon nanotubes

Publications (1)

Publication Number Publication Date
MX2016010909A true MX2016010909A (es) 2017-04-27

Family

ID=52627576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010909A MX2016010909A (es) 2014-02-21 2015-02-21 Suministro de molecula de carga util usando nanotubos de carbono discretos funcionalizados.

Country Status (10)

Country Link
US (2) US10086086B2 (es)
EP (1) EP3107581A1 (es)
JP (1) JP2017506254A (es)
KR (1) KR20160124814A (es)
CN (1) CN106232145A (es)
AU (1) AU2015218735A1 (es)
BR (1) BR112016019418A2 (es)
CA (1) CA2939617A1 (es)
MX (1) MX2016010909A (es)
WO (1) WO2015127332A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651819A1 (en) 2010-12-14 2013-10-23 Styron Europe GmbH Improved elastomer formulations
ES2577056B2 (es) * 2016-03-16 2017-01-17 Universidad De Cantabria Cobertura de nanotubos de carbono para su empleo como sistema de anclaje de dispositivos nano y micrométricos con actividad terapéutica
US20170292063A1 (en) * 2016-04-07 2017-10-12 Molecular Rebar Design, Llc Nanotube mediation of degradative chemicals for oil-field applications
EP3439673A4 (en) * 2016-04-07 2020-03-04 Molecular Rebar Design, LLC SCAFFOLDING STEM CELLS, BONES, TISSUES AND NERVES FROM DISCRETE CARBON NANOTUBES
US10638649B2 (en) * 2017-10-11 2020-04-28 Molecular Rebar Design, Llc Shielding formulations using discrete carbon nanotubes with targeted oxidation levels and formulations thereof
JP2018002789A (ja) * 2016-06-29 2018-01-11 株式会社東芝 複合材料および硬化性樹脂組成物
WO2018067711A1 (en) * 2016-10-05 2018-04-12 The Regents Of The University Of California Compositions of polymeric nanowires and methods of making and using thereof
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ
JP7058961B2 (ja) * 2017-09-20 2022-04-25 株式会社東芝 複合材料及び火力排熱回収ボイラ
KR102397787B1 (ko) * 2017-10-11 2022-05-12 몰레큘라 레바 디자인 엘엘씨 이산 탄소 나노튜브 및 건조 액체 농축물 및 그의 제제
CN112533867A (zh) * 2018-05-22 2021-03-19 钢筋分子设计有限责任公司 使用高表面积纳米管的改进型锂离子电池
US11554957B2 (en) * 2018-05-22 2023-01-17 Molecular Rebar Design, Llc Lithium ion battery using high surface area nanotubes
US10757988B1 (en) * 2020-04-07 2020-09-01 Molecular Rebar Design, Llc Personal protective equipment with functionalized nanotube compositions to control pathogens such as SARS CoV-2 (coronavirus)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523556C (en) * 2003-04-30 2011-01-11 Drexel University Thermogelling polymer blends for biomaterial applications
US20090171768A1 (en) * 2007-12-26 2009-07-02 Arjun Chopra Method and system for incentive based tie-in transaction

Also Published As

Publication number Publication date
EP3107581A1 (en) 2016-12-28
BR112016019418A2 (pt) 2018-06-12
US20160095940A1 (en) 2016-04-07
AU2015218735A1 (en) 2016-09-22
WO2015127332A1 (en) 2015-08-27
CN106232145A (zh) 2016-12-14
JP2017506254A (ja) 2017-03-02
CA2939617A1 (en) 2015-08-27
US10086086B2 (en) 2018-10-02
US20150238476A1 (en) 2015-08-27
KR20160124814A (ko) 2016-10-28

Similar Documents

Publication Publication Date Title
MX2016010909A (es) Suministro de molecula de carga util usando nanotubos de carbono discretos funcionalizados.
WO2017097862A3 (en) Occlusion device
EP4306538A3 (en) Peptide oligonucleotide conjugates
WO2017070616A3 (en) Sexually transmitted disease vaccines
MX2016016833A (es) Composiciones y metodos para la expresion de arns guias crispr que usan el promotor h1.
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2016003944A (es) Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos.
EP2722729A3 (en) Controlling contortion
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
MX2013004848A (es) Instrumento de insercion para un sistema intrauterino.
MX2023014145A (es) Oligonucleotidos modificados y metodos de uso.
EP4173615A3 (en) Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
EP2518150A3 (en) 5'Triphosphate oligonucleotide with blunt end and uses thereof
EP4241741A3 (en) Endoprosthesis delivery systems with improved retraction
WO2016025408A3 (en) Articulating rod inserter
MX2017008237A (es) Mezcla de poliamidas con fluidez mejorada.
MX2017012087A (es) Estabiizador hueco.
MX2021001545A (es) Péptidos penetrantes celulares.
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
WO2015159155A3 (en) Novel ademetionine formulations
Lladó Sedation for endoscopy in 2016-Is endoscopist-guided sedation safe in complex situations?
WO2017079403A3 (en) Polymeric nanoparticles
Al-Sinani et al. Helicobacter Pylori infection in Omani children
WO2015114633A8 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same